Fig 2: ROC curve for iFBPanel in all stages and early-stage of ESCC vs. normal control. A. The performance of the iFBPanel in distinguishing all stages and early-stage ESCC from normal controls are shown for the test cohort. B. The performance of the iFBPanel in distinguishing all stages and early-stage ESCC from normal controls are shown for the validation cohort. The area under the black line is 0.5. Abbreviation: ROC: Receiver operating characteristic; iFBPanel: EFNA1+ MMP13+ CEA+ Cyfra21-1+ SCCA; ESCC: esophageal squamous cell carcinoma.

Fig 3: Serum levels of EFNA1 and MMP13 in ESCC patients before and after surgery. (A, C) Serum levels of EFNA1 in ESCC patients before and after surgery. (B, D) Serum levels of MMP13 in ESCC patients before and after surgery. The black horizontal line in the box plot is the mean and the error line is SE. Abbreviation: ESCC: esophageal squamous cell carcinoma.

Fig 4: Gradient boosting machine for iFBPanel model construction and validation. A. iFBPanel for ESCC diagnosis in test cohort. B. iFBPanel for ESCC diagnosis in validation cohort. The area under the black line is 0.5, for reference. iFBPanel: EFNA1+ MMP13+ CEA+ Cyfra21-1+ SCCA; ESCC: esophageal squamous cell carcinoma.

Fig 5: ROC curve analysis in the diagnosis of all stages and early-stage GC. (A) The performance of the EFNA1, MMP13 and combination of EFNA1 and MMP13 in distinguishing all stages and early-stage ESCC from normal controls are shown for the test cohort. (B) The performance of the EFNA1, MMP13 and combination of EFNA1 and MMP13 in distinguishing all stages and early-stage GC from normal controls are shown for the validation cohort. The area under the black line is 0.5, for reference. ROC Receiver operating characteristic, GC gastric cancer.